English hospitals are rationing common drugs like paracetamol — not because the molecules are hard to make, but because the market to make them has been squeezed until it broke. A letter from Amanda Cole, director of the Office of Health Economics, lays out the structural trap: prices for off-patent generics and biosimilars have been driven so low that manufacturers are exiting, concentrating supply among fewer producers and leaving the entire system exposed to any disruption. The OHE's research documents the pattern clearly. When price floors collapse, the rational response for a manufacturer is to leave. Fewer suppliers means less redundancy, which means any geopolitical shock, factory shutdown, or demand spike cascades into a national shortage. The NHS then pays more — for emergency procurement, expensive substitutes, and the enormous staff burden of managing rationing in real time. Patients pay in delayed treatment and worse outcomes. Brexit compounded the fragility. The UK no longer has access to EU medicine reserves, and cross-border logistics between the UK and EU have added friction at every step. The country went from being part of a continent-scale buffer system to operating as an island with a thinner safety net — precisely when global supply chains were becoming more volatile. The core tension is not complicated: affordability versus security. The NHS needs cheap generics to function. But "cheap" has a floor below which the market stops functioning. Below that floor, the apparent savings on unit price are overwhelmed by the systemic costs of shortage — costs that are harder to see on a spreadsheet but devastatingly real in hospitals. Cole's prescription — using regulatory, pricing, and approval decisions to encourage competition and nurture supplier resilience — is directionally obvious but politically difficult. Every pound added to generic drug prices looks like a cost increase on paper. The counterfactual cost of a shortage is diffuse, delayed, and falls on patients who have no lobby. This is a textbook case of concentrated benefits (lower procurement costs now) versus dispersed costs (shortage damage later). The deeper structural question is whether the UK's pharmaceutical procurement model can distinguish between "competitive pricing" and "pricing that destroys competition." Other countries face versions of the same problem — the US FDA tracks drug shortages driven by similar market exits — but the UK's post-Brexit isolation makes its margin for error thinner. Without deliberate policy intervention to maintain a minimum viable supplier base, the current trajectory leads to more frequent, more severe shortages concentrated in exactly the medicines hospitals use most. The paracetamol shortage is the signal. The question is whether anyone acts before the next one hits something harder to substitute.
